auto_awesome
Want to know who else bid on this?
ProposalForge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Recipient
Entos Pharmaceuticals Inc.Department
National Research Council CanadaAmount
$10.0M
Province
ABType
Contribution
Agreement Number
172-2022-2023-Q4-1000363
Purpose
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity in healthy adults as a booster to approved vaccines.
Entos Pharmaceuticals Inc. × National Research Council Canada
15 grants totalling $62.2M
Industrial Research Assistance Program – Contributions to Firms
26,784 grants totalling $5.1B
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| ILLUMIN INC. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |